Medicina
Facultad
University of the Witwatersrand
Johannesburgo, SudáfricaPublicaciones en colaboración con investigadores/as de University of the Witwatersrand (66)
2024
-
Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium
The Lancet HIV
-
Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study
The Lancet HIV, Vol. 11, Núm. 6, pp. e389-e405
-
The long wait for long-acting HIV prevention and treatment formulations
The Lancet HIV
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age
HIV Medicine, Vol. 24, Núm. 1, pp. 27-36
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Effective early antiretroviral therapy in perinatal-HIV infection reduces subsequent plasma inflammatory profile
Pediatric Research, Vol. 94, Núm. 5, pp. 1667-1674
-
Genomic investigations of unexplained acute hepatitis in children
Nature, Vol. 617, Núm. 7961, pp. 564-573
-
Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial
eClinicalMedicine, Vol. 60
2022
-
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
The Lancet HIV, Vol. 9, Núm. 9, pp. e627-e637
-
Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries
Frontiers in Pediatrics, Vol. 10
-
Machine learning outperformed logistic regression classification even with limit sample size: A model to predict pediatric HIV mortality and clinical progression to AIDS
PloS one, Vol. 17, Núm. 10, pp. e0276116
-
Multiplex PCR Detection of Respiratory Tract Infections in SARS-CoV-2-Negative Patients Admitted to the Emergency Department: an International Multicenter Study during the COVID-19 Pandemic
Microbiology Spectrum, Vol. 10, Núm. 5
-
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
The Lancet HIV, Vol. 9, Núm. 9, pp. e638-e648
-
Optimizing the World Health Organization algorithm for HIV vertical transmission risk assessment by adding maternal self-reported antiretroviral therapy adherence
BMC public health, Vol. 22, Núm. 1, pp. 1312
-
Perspectives of patients, family members, health professionals and the public on the impact of COVID-19 on mental health
Journal of Mental Health, Vol. 31, Núm. 4, pp. 524-533
2021
-
Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
Infectious Diseases and Therapy, Vol. 10, Núm. 2, pp. 775-788
-
Core Outcome Measures for Trials in People with Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery
Critical Care Medicine, Vol. 49, Núm. 3, pp. 503-516
-
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
New England Journal of Medicine, Vol. 385, Núm. 27, pp. 2531-2543
-
Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight
eLife, Vol. 10